TCGA-UY-A78P-01A-12R-A36F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 78.18659658
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.650
- ALLOGRAFT_REJECTION+0.630
- INTERFERON_GAMMA_RESPONSE+0.630
- INFLAMMATORY_RESPONSE+0.570
- IL6_JAK_STAT3_SIGNALING+0.530
- TNFA_SIGNALING_VIA_NFKB+0.520
- ANGIOGENESIS+0.510
- COAGULATION+0.470
- COMPLEMENT+0.470
- PANCREAS_BETA_CELLS+0.450
Top 10 suppressed
- MITOTIC_SPINDLE-0.270
- TGF_BETA_SIGNALING-0.180
- WNT_BETA_CATENIN_SIGNALING-0.160
- UV_RESPONSE_DN-0.150
- PROTEIN_SECRETION-0.130
- NOTCH_SIGNALING-0.060
- UNFOLDED_PROTEIN_RESPONSE-0.030
- PEROXISOME-0.020
- BILE_ACID_METABOLISM+0.000
- HEME_METABOLISM+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.914 |
| 2 | MDT-AP-2131 | Med | Medulloblastoma | 0.905 |
| 3 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.902 |
| 4 | MDT-AP-2390 | Med | Medulloblastoma | 0.899 |
| 5 | TCGA-22-0940-01A-01R-0692-07 | — | cohortSQ1 | 0.898 |
| 6 | TCGA-FD-A6TD-01A-51R-A33J-07 | — | — | 0.895 |
| 7 | SRR1313165 | — | E | 0.894 |
| 8 | MDT-AP-0732 | Med | Medulloblastoma | 0.894 |
| 9 | R261 | — | — | 0.888 |
| 10 | TCGA-ZF-AA53-01A-11R-A39I-07 | — | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.650 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.630 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.570 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.510 | Remibrutinib | — uncovered |
| COAGULATION | 0.470 | Binimetinib | — uncovered |
| COMPLEMENT | 0.470 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.450 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |